Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHT101 in CD70-positive Solid Tumors
NCT06383507Phase 1Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of CHT101 in solid tumor, renal cell carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC) and 3 more, sponsored by Zhejiang University. Primary endpoint: Incidence of Adverse events after CD70 UCAR-T cells infusion at 28 days. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
CHT101
03
Conditions
solid tumorrenal cell carcinoma (RCC)head and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)ovarian cancer
Beyond the preview
Go deeper on NCT06383507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383507.